PST-809 / PulseSight Therapeutics - LARVOL DELTA

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD (GlobeNewswire) - "PulseSight Therapeutics...today announces the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial....PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA)...The planned PST-611-CT1 clinical trial aims at primarily confirming the favorable safety profile of PST-611 administration and is expected to start Q2 2025, subject to the regulatory greenlight, with readout anticipated end 2025/early 2026....The Series A financing remains open to new investors, to provide funds to support PST-611 Phase IIa clinical trial preparation and implementation, as well as the development of PulseSight’s wider portfolio of non-viral vectorized therapies including PST-809, a potential first-in-class therapy for wet AMD that comprises a dual-gene plasmid encoding..."

Financing • New P2a trial • P2a data • Regulatory • Dry Age-related Macular Degeneration • Ophthalmology

Revolutionizing neovascular AMD treatment: Electrotransfection‐based dual‐gene therapy platform (ESGCT 2023) - "Furthermore, in the neuroretina, EYS809 downregulated the expression of extracellular matrix-related genes (MMP2, COL1A1, and COL4A1) involved in subretinal fibrosis. Collectively, these findings underscore the potential for EYS809 to promote sustained disease regression and diminish the need for anti-VEGF injections over the long term."

Gene therapy • Fibrosis • Gene Therapies • Immunology • Retinal Disorders • Wet Age-related Macular Degeneration • COL1A1 • COL4A1 • MMP2

Efficacy and durability of EYS809 non-viral gene therapy in nAMD preclinical models (ARVO 2023) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Gene therapy • Preclinical • Ophthalmology

[VIRTUAL] EYS809 Non-Viral Gene Therapy to Improve Convenience and Outcomes in Wet AMD (ARVO 2021) - "Our non-viral gene therapy sustained drug delivery approach to deliver anti-VEGF proteins to the eye could be a viable alternative to repeated IVT injections that have been associated with poor visual outcomes in wet AMD patients. The combined effect of aflibercept and DCN, expressed from the EYS809 dual-gene plasmid, is expected to provide benefits over aflibercept alone by also reducing CNV and subretinal fibrosis."

Age-related Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration • TGFB1